Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2022-09-12 00:00:00 ET · period of report 2022-09-09 · accession 0001883850-22-000067 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-09-12 | 2022-09-09 | REGN | LAROSA JOSEPH J | EVP GC, Secret | M - OptEx | $270.43 | +30.0K | 41.6K | +259% | +$8.11M |
| D | 2022-09-12 | 2022-09-09 | REGN | LAROSA JOSEPH J | EVP GC, Secret | F - Tax | $730.96 | -20.7K | 20.9K | -50% | -$15.15M |
| D | 2022-09-12 | 2022-09-09 | REGN | LAROSA JOSEPH J | EVP GC, Secret | M - OptEx | $0.00 | -30.0K | 10.0K | -75% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-09 | M | A | 30,000 | $270.43 | 41,580 | D | — | — | |
| 2 | Common | Common Stock | 2022-09-09 | F | D | 20,730 | $730.96 | 20,850 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-09-09 | M | D | 30,000 | $0.00 | 10,000 | D | $270.43 · — to 2023-12-13 | 30,000 Common Stock | (F1) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |